$2.49
2.89% yesterday
Nasdaq, Oct 13, 10:00 pm CET
ISIN
US7163821066
Symbol
PETS

PetMed Express, Inc. Stock price

$2.49
-0.32 11.39% 1M
-0.53 17.55% 6M
-2.33 48.34% YTD
-1.51 37.75% 1Y
-17.98 87.84% 3Y
-29.57 92.23% 5Y
-13.77 84.69% 10Y
-6.62 72.67% 20Y
Nasdaq, Closing price Mon, Oct 13 2025
+0.07 2.89%

Key metrics

Basic
Market capitalization
$51.4m
Enterprise Value
$1.3m
Net debt
positive
Cash
$50.1m
Shares outstanding
20.7m
Valuation (TTM | estimate)
P/E
249.0 | negative
P/S
0.2 | 0.2
EV/Sales
0.0 | 0.0
EV/FCF
1.6
P/B
0.5
Dividends
DPS
$1.20
Yield 1Y | 5Y
48.2% | 4.2%
Growth 1Y | 5Y
0.0% | 7.1%
Payout 1Y | 3Y
12,000.0% | 137.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$247.0m | $236.4m
EBITDA
$8.4m | $3.5m
EBIT
$1.5m | $3.8m
Net Income
$360.0k | $-5.1m
Free Cash Flow
$860.0k
Growth (TTM | estimate)
Revenue
-10.8% | -15.9%
EBITDA
227.0% | 413.8%
EBIT
111.9% | 147.2%
Net Income
104.4% | 32.2%
Free Cash Flow
-50.0%
Margin (TTM | estimate)
Gross
27.7%
EBITDA
3.4% | 1.5%
EBIT
0.6%
Net
0.1% | -2.1%
Free Cash Flow
0.4%
Financial Health
Equity Ratio
56.9%
Return on Equity
-7.7%
ROCE
1.6%
ROIC
0.3%
Debt/Equity
0.0
More
EPS
$0.0
FCF per Share
$0.0
Short interest
8.7%
Employees
287
Rev per Employee
$980.0k
Show more

Is PetMed Express, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,002 stocks worldwide.

PetMed Express, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a PetMed Express, Inc. forecast:

2x Hold
33%
4x Sell
67%

Analyst Opinions

6 Analysts have issued a PetMed Express, Inc. forecast:

Hold
33%
Sell
67%

Financial data from PetMed Express, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
247 247
11% 11%
100%
- Direct Costs 179 179
10% 10%
72%
68 68
12% 12%
28%
- Selling and Administrative Expenses 60 60
29% 29%
24%
- Research and Development Expense - -
-
-
8.38 8.38
227% 227%
3%
- Depreciation and Amortization 6.86 6.86
12% 12%
3%
EBIT (Operating Income) EBIT 1.52 1.52
112% 112%
1%
Net Profit 0.36 0.36
104% 104%
0%

In millions USD.

Don't miss a Thing! We will send you all news about PetMed Express, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PetMed Express, Inc. Stock News

Neutral
GlobeNewsWire
about 17 hours ago
SAN FRANCISCO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Investors in PetMed Express (NASDAQ: PETS) have seen the price of their shares steadily decline by about 26% since June 16, 2025, when the company announced it would not timely file its annual financial statements for its year ended March 31, 2025. Later disclosures reveal serious additional company problems.
Neutral
Business Wire
4 days ago
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of PetMed Express, Inc. (“PetMed” or the “Company”) (NASDAQ: PETS) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON PETMED EXPRESS, INC. (PETS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR ...
Neutral
PRNewsWire
4 days ago
SAN FRANCISCO , Oct. 10, 2025 /PRNewswire/ -- Investors in PetMed Express (NASDAQ: PETS) have seen the price of their shares steadily decline by about 26% since June 16, 2025, when the company announced it would not timely file its annual financial statements for its year ended March 31, 2025. Later disclosures reveal serious additional company problems.
More PetMed Express, Inc. News

Company Profile

PetMed Express, Inc. engages in the provision of markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The firm markets its products through national television, online and direct mail or print advertising campaigns. The company was founded in January 1996 and is headquartered in Delray Beach, FL.

Head office United States
CEO Sandra Campos
Employees 287
Founded 1996
Website www.1800petmeds.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today